A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss

Recruiting 24 enrolled Yilai Shu

Non-randomizedSequentialOpen-labelTreatment

Summary

The study is designed to evaluate the safety, tolerability, and preliminary efficacy of EH002 for the treatment of congenital deafness caused by mutations in the OTOF gene. Participants may receive one or two injections of the EH002 gene therapy in one or both ears.

Timeline

Start: 2024-11-22
Primary completion: 2027-11
Completion: 2029-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EH002	Unknown	0.025 ml	Other
Subject	EH002	Unknown	0.05 ml	Other
Subject	EH002	Unknown	0.1 ml	Other
Subject	EH002	Unknown	0.15 ml	Other

A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss

Summary

Timeline

Drugs

Indications